Daclatasvir

Details

Files

Generic Name:

Daclatasvir

Project Status:

Complete

Therapeutic Area:

Hepatitis C, Chronic

Manufacturer:

Bristol-Myers Squibb Canada Inc.

Call for patient/clinician input open:

January 19, 2015

Brand Name:

Daklinza

Project Line:

Reimbursement Review

Project Number:

SR0417-000

Call for patient/clinician input closed:

March 10, 2015

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Hepatitis C, chronic

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

September 21, 2015

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Patient Group Input Submissions View PDF

Last Updated : February 13, 2015